Uric acid levels in patients on antitubercular therapy at Dr. B.R. Ambedkar Medical College, Bengaluru
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 4, Pages 354-357
AbstractBackground: Tuberculosis is an infectious disease caused by mycobacterium tuberculosis. The disease burden is huge in developing country like India. Antitubercular therapy is the mainstay of treatment. The drugs in the therapy can cause various adverse effects. Hyperuricemia is one of the adverse effects caused. Aim: To estimate the levels of serum uric acid level in patients taking antitubercular therapy including pyrazinamide. Materials and Methods: A prospective study done at DR. BR AMC and H including the 60 patients on antitubercular therapy. Serum uric acid levels are estimated at 0 and 8 weeks of therapy. Results: Hyperuricemia was significant in patients receiving antitubercular therapy with pyrazinamide. Serum urate level 6.7 +/- 0.6 mg/dl compared to baseline 4.3+/- 0.8 mg/dl. Hyperuricemia was seen in 46.6%. Conclusion: Patients on antitubercular therapy including pyrazinamide developed significant hyperuricemia.
- Article View: 70
- PDF Download: 99